About Medpace Holdings, Inc. - Common Stock (MEDP)
Medpace Holdings Inc is a global contract research organization (CRO) that specializes in providing a range of services to the pharmaceutical and biotechnology industries. The company supports clients throughout the drug development process, offering expertise in clinical trials, regulatory compliance, and data management. Medpace focuses on delivering efficient and high-quality clinical services across various therapeutic areas, helping to streamline the path from clinical research to market approval. Through its integrated approach, the company aims to accelerate the development of new treatments while ensuring adherence to safety and regulatory standards. Read More
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q2 CY2025, with sales up 14.2% year on year to $603.3 million. The company’s full-year revenue guidance of $2.47 billion at the midpoint came in 13% above analysts’ estimates. Its GAAP profit of $3.10 per share was 3.5% above analysts’ consensus estimates.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP)
jumped 49.3% in the morning session after the company reported strong second-quarter financial results and raised its full-year guidance.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 14.2% year on year to $603.3 million. The company’s full-year revenue guidance of $2.47 billion at the midpoint came in 13% above analysts’ estimates. Its GAAP profit of $3.10 per share was 3.5% above analysts’ consensus estimates.
Medpace Holdings shares are soaring in Monday's after-hours session after the company reported strong financial results for the second quarter and raised its full-year guidance.
